Gastroenterology

Dose de-escalation of tofacitinib resulted in less hospitalizations for patients with ulcerative colitis.

The potential for personalized medicine in inflammatory bowel disease might. be realized in the next few years.

Upadacitinib was not approved by the FDA until 2022 for patients with ulcerative colitis.

The 12-24 session counseling program also resulted in improvements in sleep quality, fatigue level, and stress levels for patients with inflammatory bowel disease.

The majority of patients who achieved persistence at the 12 month mark were also corticosteroid free.

The product is a combination of herbal compounds curcumin and QingDai called CurQD.

Microscopic inflammation can be an important indicator of disease activity in patients with ulcerative colitis.

The prevalence of advanced colorectal neoplasms was higher in men and older individuals.

There was no differences in serious adverse event rates between patients treated with the combination therapy and patients who withdrew from infliximab or immunosuppressant therapy.

The guidelines include advocating for more preventative care and changing how the disease is diagnosed.

Dupilumab is currently the only treatment for eosinophilic esophagitis approved by the US Food and Drug Administration.

Nearly half of patients treated with vonoprazan 10 mg and 20 mg achieved more 24-hour heartburn free days compared to participants treated by placebo.

Gut microbiota diversity was lower in below average responders, while 39.5% of participants had a serological response below the geometric mean.

Experts in gastroenterology share advice for the treatment of patients of Crohn’s disease.

There have been more than 12,900 studies on the involvement of dysbiosis in the gensisinfectious diseases in the last 15 years.

More patients are presenting with later stage liver cancer due to missed screenings during the COVID-19 pandemic.

The World Health Organization has set a goal of eradication for HCV by 2030.

The FDA requested additional data showing the levels of a nitrosam impurity was below the set threshold throughout the life of vonoprazan.

Ulcerative colitis was considered an independent risk factor, while Crohn’s disease and unclassified inflammatory bowel disease were not.

Dr Anita Afzali and Miguel Regueiro discuss emerging therapies and combinations in the pipeline for Crohn’s disease as well as unmet needs in the field for disease management.

Bincy P. Abraham, MD, MS, AGAF, FACG, and Jennifer Seminerio, MD, comment on emerging data for interchangeability of biosimilars and biologics when treating Crohn’s disease.

Previous trials using acupuncture in patients with irritable bowel syndrome have suffered from problems of high placebo response rates.

Experts in gastroenterology review the use of IL-23 inhibitors such as guselkumab and risankizumab-rzaa for the management of Crohn’s disease.

Dr Bincy P. Abraham examines age considerations and comorbidities when choosing a therapy for elderly patients with Crohn’s disease.

In part A of the trial, 60% of patients treated with dupilumab weekly met the primary endpoint of histologic remission, compared to 5% of the placebo group.